Background High triglyceride levels are associated with increased cardiovascular risk, but
whether reductions in these levels would lower the incidence of cardiovascular events is�…

Observational, genetic, and experimental data indicate that triglyceride rich lipoproteins
(TRLs) likely participate causally in atherothrombosis. Yet, robust clinical trial evidence that�…

Background Using a meta-analysis of randomized controlled trials (RCTs), this study aimed
to investigate the efficacy and safety of pemafibrate, a novel selective peroxisome�…

Aim: To verify the superiority of pemafibrate over placebo and the non-inferiority of
pemafibrate to the maximum dose of fenofibrate for determining the percent change in�…

Despite best evidence-based treatment including statins, residual cardiovascular risk poses
a major challenge for clinicians in the twenty first century. Atherogenic dyslipidaemia, in�…

Background To overcome the concerns associated with the use of fibrates, pemafibrate (K-
877), a novel selective peroxisome proliferator-activated receptor modulator, was�…

OBJECTIVE Type 2 diabetes is frequently complicated with atherogenic dyslipidemia. This
study aimed to evaluate the efficacy and safety of pemafibrate (K-877) in patients with type 2�…

Abstract Purpose of Review Reduction of serum low-density lipoprotein cholesterol (LDL-C)
levels by statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9)�…

An elevated serum level of LDL cholesterol is a well-known risk factor for cardiovascular
disease (CVD), but the role of elevated triglyceride levels is debated. Controversies�…

OBJECTIVE High plasma triglyceride (TG) is an independent risk factor for cardiovascular
disease. Fibrates lower TG levels through peroxisome proliferator–activated receptor α�…